Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-10-18 12:29 pm Sale | 13G | Vir Biotechnology Inc. VIR | STATE STREET CORP STT | 5,625,533 4.100% | -1,286,549 (-18.61%) | View |
2024-02-13 5:17 pm Purchase | 13G | Vir Biotechnology Inc. VIR | VANGUARD GROUP INC | 12,297,139 9.140% | 2,202,638 (+21.82%) | View |
2024-02-13 5:00 pm Purchase | 13G | Vir Biotechnology Inc. VIR | SB INVESTMENT ADVISERS (UK) LTD | 16,684,041 12.400% | 16,684,041 (New Position) | View |
2024-01-24 07:59 am Purchase | 13G | Vir Biotechnology Inc. VIR | STATE STREET CORP STT | 6,912,082 5.140% | 6,912,082 (New Position) | View |
2024-01-23 4:14 pm Purchase | 13G | Vir Biotechnology Inc. VIR | BlackRock Inc. BLK | 16,864,579 12.500% | 2,727,951 (+19.30%) | View |
2023-02-14 4:07 pm Sale | 13G | Vir Biotechnology Inc. VIR | SOFTBANK VISION FUND (AIV M1) L.P. | 20,259,535 15.200% | -2,357,131 (-10.42%) | View |
2023-02-09 11:35 am Purchase | 13G | Vir Biotechnology Inc. VIR | VANGUARD GROUP INC | 10,094,501 7.580% | 2,764,370 (+37.71%) | View |
2023-01-24 1:56 pm Purchase | 13G | Vir Biotechnology Inc. VIR | BlackRock Inc. BLK | 14,136,628 10.600% | 752,434 (+5.62%) | View |
2022-09-13 3:45 pm Sale | 13D | Vir Biotechnology Inc. VIR | ARCH Venture Fund IX L.P. | 13,552,310 10.200% | -5,636,784 (-29.37%) | View |
2022-09-08 1:43 pm Purchase | 13G | Vir Biotechnology Inc. VIR | BlackRock Inc. BLK | 13,384,194 10.100% | 13,384,194 (New Position) | View |
2022-05-10 5:05 pm Purchase | 13D | Vir Biotechnology Inc. VIR | ARCH Venture Fund IX L.P. | 19,189,094 14.700% | 3,374 (+0.02%) | View |
2022-02-14 4:05 pm Sale | 13G | Vir Biotechnology Inc. VIR | SCANGOS GEORGE A | 6,266,581 4.790% | -734,727 (-10.49%) | View |
2022-02-11 11:19 am Sale | 13G | Vir Biotechnology Inc. VIR | Capital International Investors | 5,634,019 4.300% | -5,806,552 (-50.75%) | View |
2022-02-10 4:46 pm Purchase | 13G | Vir Biotechnology Inc. VIR | GSK plc GSK | 8,550,954 6.500% | 1,924,927 (+29.05%) | View |
2022-02-10 08:42 am Purchase | 13G | Vir Biotechnology Inc. VIR | VANGUARD GROUP INC | 7,330,131 5.600% | 7,330,131 (New Position) | View |
2022-01-10 5:02 pm Sale | 13D | Vir Biotechnology Inc. VIR | ARCH Venture Fund IX L.P. | 19,185,720 14.700% | -2,589,653 (-11.89%) | View |
2021-07-12 5:02 pm Sale | 13D | Vir Biotechnology Inc. VIR | ARCH Venture Fund IX L.P. | 21,775,373 16.700% | -4,915,244 (-18.42%) | View |
2021-04-14 5:23 pm Sale | 13D | Vir Biotechnology Inc. VIR | ARCH Venture Fund IX L.P. | 26,690,617 20.900% | -1,976,046 (-6.89%) | View |
2021-02-16 2:24 pm Unchanged | 13G | Vir Biotechnology Inc. VIR | Capital International Investors | 11,440,571 9.000% | 0 (Unchanged) | View |
2021-02-16 1:57 pm Purchase | 13G | Vir Biotechnology Inc. VIR | Capital International Investors | 11,440,571 9.000% | 11,440,571 (New Position) | View |